Board of Managers

Bernard Lyons, Ph.D.

Dr. Lyons is a senior healthcare executive and medtech industry consultant.  He has over 40 years of experience in the medical device field.  Dr. Lyons was President and Chief Executive Officer at Direct Flow Medical, Inc. from February 2006 until he retired in May 2015.  Prior to Direct Flow, he served as President and CEO of Vasca, Inc. a later stage, privately held medical device company focused on subcutaneous vascular access ports for hemodialysis treatment in patients with end stage renal disease. Previously Dr. Lyons was President and CEO of CardioClasp, Inc. a development stage start-up medical device company focused on the treatment of congestive heart failure.  Dr. Lyons held several senior level positions at Boston Scientific Corporation during his 15 year tenure where he was the Vice President, Sales & Marketing for Interventional Oncology; Vice President, Sales & Marketing of the Meadox Division; Vice President, Corporate Product Development; and President of Boston Scientific’s operations in Japan. Dr. Lyons is a member of the Board of Directors for Minnetronix, Inc. (St. Paul, MN), Vitara Medical, Inc. (Philadelphia, PA) and REVA Medical, Inc. (San Diego, CA).  He was previously a Director at Paramit Corp. (Morgan Hill, CA) and Creganna Medical (Galway, Ireland).  He is a guest lecturer at the Tuck Business School and Thayer School of Engineering at Dartmouth College where he serves on the Board of Directors for Insight Surgical Technologies, LLC and was previously a Director for CairnSurgical, Inc. (Lebanon, NH).  He is also a guest lecturer with the BioInnovate Program at the National University of Ireland, Galway where he previsoulsy held Board and advisory roles with Vetex Medical, LTD and CrannMed, LTD (Galway, Ireland).  Dr. Lyons is currently an Operating Partner with Altaris Capital (New York, NY) and is an Executive in Residence at Partners HealthCare Innovation (Boston, MA) working with Canon USA (Cambridge, MA) as a business advisor.  He was an Instructor in Surgery at Dartmouth Medical School and Adjunct Assistant Professor at the Thayer School of Engineering at Dartmouth College. Dr. Lyons earned his Ph.D. in Cancer Biology from Stanford University School of Medicine and a B.A. from the University of California, Los Angeles.

Jeff Anderson

Jeffrey Anderson was appointed our President in March 2019. Prior to that he served as our Senior Vice President of Clinical and Regulatory affairs since December 2013, overseeing all aspects of the clinical evaluation and regulatory approval of the Company’s products as well as the commercial launch in several key markets. Previously, he served as our Vice President of Clinical and Regulatory affairs from 2004 to 2008, and again from February 2011 until his promotion to Senior Vice President. He has over 25 years of experience in the medical device industry, including his positions of Vice President of Clinical & Regulatory Affairs and Vice President of Research & Development for Neomend, a biomedical device company engaged in the development and commercialization of surgical wound healing products, where he served from October 2008 through February 2011. Additionally, Mr. Anderson has held senior positions at Abbott Vascular, Jomed, CRS Clinical Research, and Medtronic. He received his B.S. in Physics from California State University at Fullerton.

Louis A. Cannon, M.D.

Louis A. Cannon, MD, is the Founder and Senior Managing Director of BioStar Ventures and BioStar Capital.  Dr. Cannon is also the President and Founder of The Cardiac & Vascular Research Center of Northern Michigan and the Co Moderator of the “Shark Tank” TCT / CRF Medical Design Innovation and Technology Forum Affiliated with the Columbia University Vagelos College of Physicians and Surgeons New York, New York

Dr. Cannon brings a unique combination of interventional cardiology expertise, business, medical device innovation, technology transfer, proven leadership, venture capital and private equity experience, education, and research along with uncompromising ethics in patient care.

He is quadruple boarded in Emergency Medicine, Internal Medicine, Interventional Cardiology and graduated in the Alpha Omega Alpha Honor society from the Boonshoft School of Medicine . He pursued his training in Invasive Cardiology and Interventional Cardiology at the University Hospital of Cincinnati.

Dr. Cannon has served as the Principal Investigator in numerous clinical trials throughout his career and is a well-respected leader in both Interventional Cardiology as well as Venture Investing.

Nick Taylor

Nick’s interest in Reva began when he invested in the 2011 IPO, and intensified with his instrumental role in the design and structure of the various further rounds of financing in 2014 and 2017.  He has been deeply involved in the company’s strategy, and has introduced key investors.  His extensive career in investing began at Goldman Sachs, he currently works as a portfolio manager in event-driven and special situation investing, which he has done since 1996, managing teams within large financial organisations.  Nick co-founded and subsequently ran Modal Capital Partners, an international event-driven captive hedge fund between 1999 and 2008, was head of Asia-Pacific Proprietary trading for Credit-Suisse, founded and ran Senrigan Capital, an Asia based Event-Driven fund, and was a Senior Managing Director and head of International Principal investments for Citadel.  Nick has set up offices in Tokyo, Hong Kong, London, and Bermuda (a reinsurance company, Modal Re).  He is on the Board of Silver Creek Pharmaceuticalsl and Flowers art gallery.  Nick has an M.A. in Philosophy from Cambridge University, and was a student for D.Phil in Philosophy at Balliol College, Oxford. Prior to moving into an investing career he was a college lecturer in Philosophy at St. Catherine’s college Oxford.

Tamara Elias, M.D.

Tamara Elias, M.D. has been avidly involved with healthcare for over 20 years across a wide spectrum of diverse experiences, beginning with medical school, extending into surgical residency, followed by healthcare strategic consulting, private equity investing, corporate strategy and business development, product innovation and P&L, inclusive of board member positions.

Currently, in her role as VP, Global Partnerships & Innovation at Merck, Tamara leads global “non-product” (“around the pill”) commercial partnerships for Human Health with start-ups and established players across the value chain. Her team’s work includes building new journeys to care for patients by partnering with 3rd parties, scouting of relevant partners, execution of win-win contracts and deal structures, partnering with markets to share best practices and scale based on local successes, and external monitoring of key healthcare trends as it affects our business.

Her prior role was with Aetna as VP, Clinical Product Development, owning a $20M P&L, where she focused on optimizing and rationalizing the existing clinical product portfolio for all lines of business. At Becton Dickinson, she was VP, Corporate Strategy and Business Development for the $8B revenue Medical Segment.  In this role, Tamara engineered the creation of the Digital Health Business Unit – from designing the organization to securing funding to hiring the team and getting the approval of the first concept in digital diabetes (now launched). She was a member of the Leadership Team and worked to advance the overall strategic direction and growth for the medical segment, including the $24B acquisition of CR Bard which closed in December 2017.

Tamara joined Becton Dickinson from Essex Woodlands Healthcare Partners, a private equity firm, where she was a Partner and co-led the healthcare services and healthcare IT growth equity practice and assisted with the management of the medical device growth equity portfolio and practice. In over 8 years with the firm, she served on several boards.

Prior to Essex Woodlands, Tamara spent five years as a strategy consultant at McKinsey, where she advised pharmaceutical, diagnostic and device companies in product commercialization and M&A.

Tamara currently serves on the Board of Directors of Avinger (NASDAQ: AVGR), a public medtech company in the PVD space, as Chairman of the Nominating/Governance Committee and a Member of the Audit and Comp Committees, as well as on the board of REVA Medical LLC, also in the PVD space and BehaVR in the mental health arena.

Tamara holds a BA in both Biology and Anthropology from Yale University, obtained her M.D. from The Johns Hopkins School of Medicine, and pursued a general surgery residency at Massachusetts General Hospital.